Bezafibrate

Specifications

41859-67-0CAS Number

255-567-9EC Number

2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acidIUPAC Name

C19H20ClNO4Chemical Formula

361.8 g/molMolecular Weight

bezafibrate; 41859-67-0; Bezalip; Bezafibrato; Bezatol SR; Bezafibratum; BM-15.075; BM-15075; DTXSID3029869; BM 15.075; NSC-758174; Y9449Q51XH; Propanoic acid, 2-(4-(2-((4-chlorobenzoyl)amino)ethyl)phenoxy)-2-methyl-; DTXCID909869; CHEBI:47612; Propanoic acid, 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl-; Beza Lande; Beza Puren; BM15.075; Bezalip-mono; Fibrazate xl; Zimbacol xl; Bezagen xl; Liparol xl; RefChem:58600; C10AB02; 255-567-9; Cedur; Befizal; Bezafibrat; Sklerofibrat; Azufibrat; Bezafibratum [INN-Latin]; Bezafibrato [INN-Spanish]; Bezatol SR (TN); 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid; 2-(4-(2-(4-Chlorobenzamido)ethyl)phenoxy)-2-methylpropanoic acid; 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid; MFCD00078970; Difaterol; Bezatol; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl-propanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid; MLS000028533; CHEMBL264374; durabezur; Reducterol; Bezabeta; Bezacur; Bezamerck; Eulitop; Solibay; Lipox; Bezafibrat PB; Beza-Lande; Beza-Puren; Regadrin B; 2-(4-{2-[(4-chlorophenyl)formamido]ethyl}phenoxy)-2-methylpropanoic acid; BM15075; NCGC00016850-01; SMR000058298; Bezafibrato [Spanish]; Bezalip Retard; CAS-41859-67-0; BF-759; Bezafibrate-d6 (dimethyl-d6); 2-{4-[2-(4-chlorobenzamido)ethyl]phenoxy}-2-methylpropanoic acid; BM 15075; LO 44; 2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid; 2-[P-[2-P-CHLOROBENZAMIDO)ETHYL]PHENOXY]-2-METHYLPROPIONIC ACID; CCRIS 9085; SR-01000000106; EINECS 255-567-9; BRN 4267656; UNII-Y9449Q51XH; Bezafibrate CRS; Bezalip SR; Bezafibrate [USAN:INN:BAN:JAN]; PEM; Prestwick_724; BENAFIBRATE; a-[4-(4-chlorobenzoylaminoethyl)phenoxy]isobutyric acid; Bezafibrate (Standard); Spectrum_001443; Opera_ID_376; BEZAFIBRATE [MI]; Prestwick0_000378; Prestwick1_000378; Prestwick2_000378; Prestwick3_000378; Spectrum2_000922; Spectrum3_001500; Spectrum4_000325; Spectrum5_001079; Spectrum5_001967; BEZAFIBRATE [INN]; BEZAFIBRATE [JAN]; BEZAFIBRATE [USAN]; BEZAFIBRATE [MART.]; SCHEMBL16299; BEZAFIBRATE [WHO-DD]; BSPBio_000535; BSPBio_001314; BSPBio_003119; KBioGR_000034; KBioGR_000669; KBioSS_000034; KBioSS_001923; MLS001148205; Bezafibrate, >=98%, solid; DivK1c_000092; SPECTRUM1502046; SPBio_000824; SPBio_002456; BPBio1_000589; GTPL2668; orb1225084; orb1310243; orb3025853; Bezafibrate - Bio-X trade mark; BDBM28701; Bezafibrate (JP18/USAN/INN); HMS500E14; HY-B0637R; KBio1_000092; KBio2_000034; KBio2_001923; KBio2_002602; KBio2_004491; KBio2_005170; KBio2_007059; KBio3_000067; KBio3_000068; KBio3_002619; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]isobutyric Acid; NINDS_000092; BEZAFIBRATE [EP MONOGRAPH]; Bio2_000034; Bio2_000514; HMS1361B16; HMS1569K17; HMS1791B16; HMS1921H16; HMS1989B16; HMS2089F04; HMS2092B12; HMS2096K17; HMS2233E22; HMS3261D21; HMS3369B13; HMS3402B16; HMS3650K22; HMS3652M22; HMS3713K17; HMS5082C22; Pharmakon1600-01502046; HY-B0637; MSK10345; UYB80274; Tox21_110645; Tox21_301845; Tox21_500500; CCG-39683; EBC-26794; NSC758174; s4159; AKOS005107743; Propionic acid, 2-(4-(2-((4-chlorobenzoyl)amino)ethyl)phenoxy)-2-methyl-; Tox21_110645_1; AB03023; AC-6817; DB01393; FB18580; HS-0040; LP00500; NSC 758174; SB17361; SDCCGSBI-0051715.P003; IDI1_000092; IDI1_033784; Bezafibrate 100 |Ig/mL in Acetonitrile; NCGC00016850-02; NCGC00016850-03; NCGC00016850-04; NCGC00016850-05; NCGC00016850-06; NCGC00016850-07; NCGC00016850-08; NCGC00016850-09; NCGC00016850-10; NCGC00016850-11; NCGC00016850-12; NCGC00016850-15; NCGC00016850-19; NCGC00016850-25; NCGC00023317-03; NCGC00023317-04; NCGC00023317-05; NCGC00023317-06; NCGC00023317-07; NCGC00023317-08; NCGC00255376-01; NCGC00261185-01; BB166159; Bezafibrate, analytical reference material; SY052507; Bezafibrate 100 microg/mL in Acetonitrile; SBI-0051715.P002; DB-238976; AB00052265; B3346; NS00000219; ST51014927; SW196871-4; D01366; D70191; AB00052265-15; AB00052265_16; AB00052265_17; EN300-18539646; F544300; Q577387; SR-01000000106-3; SR-01000000106-4; SR-01000000106-5; BRD-K46018455-001-06-0; BRD-K46018455-001-17-7; BRD-K46018455-001-26-8; BRD-K46018455-001-27-6; SR-01000000106-10; Bezafibrate Working Standard (Secondary Reference Standard); Bezafibrate, European Pharmacopoeia (EP) Reference Standard; 2-(4-(2-parachlorobenzamidoethyl)phenoxy)-2-methylpropionic acid; 2-[4-[2-(4-chlorobezamide)ethyl]phenoxy]-2-methylpropanoic acid; 2-[4-[2-[(4-Chlorobenzoyl)amino]ethyl]phenoxyl]-2-methylpropanoic Acid; 2-(4-{2-[(4-chlorophenyl)carbonylamino]ethyl}phenoxy)-2-methylpropanoic acid; 2-[4-(2-{[(4-chlorophenyl)carbonyl]amino}ethyl)phenoxy]-2-methylpropanoic acidSynonyms